by Stacey Hawkins | Apr 14, 2020 | Neuroscience
Multiple SCLEROSIS Awareness March is Multiple Sclerosis (MS) Awareness Month, so this WEEKLY takes a look at the science behind the disease and some of the treatments developed for it. MS typically occurs in susceptible individuals between the ages of 20 and 50, and... 
by Stacey Hawkins | Jun 17, 2019 | Groundbreaking New Therapies in Development
A Pathway Lies In The Bridge Between Cells As any high school biology teacher will happily remind us, cells are the basic building blocks of all living things: you, the office ficus tree, the yeast that bubbles your beer. In animals, cells join to form tissues and... 
by Stacey Hawkins | Feb 7, 2019 | Groundbreaking New Therapies in Development
Decoding The Gut-Brain Axis Earlier this week, a newly published study made headlines for showing a direct link between the gut microbiome and depression. For the past several years, scientists have suspected a link between bugs in the gut and neurological health.... 
by Stacey Hawkins | May 25, 2017 | Immunotherapies
The Drug Kingpins Monoclonal antibodies (mAbs) are the undisputed drug kingpins. In 2013, the mAb market raked in $75 billion in combined sales, covering a whole range of indications from cancer and infectious disease, to autoimmune disorders, and even high... 
by Stacey Hawkins | Dec 7, 2016 | Neuroscience
Microbiome & Disease The biotech world is abuzz with talk of the latest microbiome startup launch Axial Biotherapeutics (Boston, MA). What caught our eye here at the WEEKLY is the company’s focus on the gut microbiome — the entire collection of microbes living in...
